YTG treats IPF by regulating the PI3K-AKT signaling pathway, MAPK signaling pathway, and other pathways that inhibit the EMT process, fibroblast proliferation, fibroblast-to-myofibroblast cell conversion, apoptosis resistance of myofibroblasts, collagen expression, and other mechanisms. Here, PIK3CG is linked to idiopathic pulmonary fibrosis.